| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $108,136,568 ) (Continued on the next page) |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG1CA233332 | ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC) | 000 | 6 | NIH | 3/12/2025 | $535,627 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA278599 | Mechanisms of racial disparity in breast cancer-related lymphedema | 000 | 3 | NIH | 12/20/2024 | $661,096 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01DK128615 | Genetic susceptibility to Barrett's esophagus: From GWAS to biology | 000 | 4 | NIH | 11/18/2024 | $751,138 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA286918 | Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate | 001 | 2 | NIH | 6/24/2025 | $715,058 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA283378 | Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis | 000 | 3 | NIH | 5/28/2025 | $734,550 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA286721 | Dissecting FOSL1-mediated lineage plasticity and resistance to androgen receptor signaling inhibition in prostate cancer | 000 | 2 | NIH | 4/14/2025 | $173,016 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AG067598 | Chaperome networks in Alzheimer's disease | 000 | 5 | NIH | 1/23/2025 | $1,033,893 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA283306 | Integrating Electronic Patient-Reported Outcomes into Discharge Planning | 000 | 2 | NIH | 5/26/2025 | $210,014 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290231 | Targeting isocitrate dehydrogenase mutations by enzyme hyperactivation | 001 | 2 | NIH | 6/3/2025 | $47,475 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290231 | Targeting isocitrate dehydrogenase mutations by enzyme hyperactivation | 000 | 2 | NIH | 1/16/2025 | $427,285 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA286330 | Acupuncture to Improve Outcomes in Patients with Sepsis: a Randomized Controlled Trial | 000 | 2 | NIH | 1/23/2025 | $222,156 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA281928 | Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer | 000 | 3 | NIH | 5/29/2025 | $734,548 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM152667 | Mechanism and Significance of HMG Co-A Synthase 1 Degradation | 000 | 2 | NIH | 3/26/2025 | $330,130 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM152017 | Teaching free energy calculations to learn | 001 | 2 | NIH | 2/25/2025 | $484,704 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01EB033000 | Multicolor PET to interrogate cancer biology | 000 | 3 | NIH | 3/20/2025 | $605,806 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288880 | Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer | 001 | 2 | NIH | 5/26/2025 | $40,260 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288880 | Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer | 000 | 2 | NIH | 3/12/2025 | $362,340 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG3CA290241 | CD28-KITv CAR T cells with PD-1 dominant negative receptor | 001 | 2 | NIH | 5/22/2025 | $157,035 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297013 | Developing and Validating Prognostic Models for Black women with Endometrial Cancer following Hysterectomy | 000 | 1 | NIH | 2/13/2025 | $132,825 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG3CA290241 | CD28-KITv CAR T cells with PD-1 dominant negative receptor | 000 | 2 | NIH | 2/13/2025 | $1,413,307 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA227636 | Molecular Glues to Target RAS-MAPK Driven Cancers | 001 | 9 | NIH | 5/22/2025 | $47,951 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA227636 | Molecular Glues to Target RAS-MAPK Driven Cancers | 000 | 9 | NIH | 2/13/2025 | $431,567 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297011 | Targeting the evolving immunopeptidome of metastatic colorectal cancer | 000 | 1 | NIH | 2/13/2025 | $154,642 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA251591 | Predicting sensitivity and resistance in RET-driven cancers | 001 | 5 | NIH | 5/22/2025 | $40,489 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA251591 | Predicting sensitivity and resistance in RET-driven cancers | 000 | 5 | NIH | 3/17/2025 | $364,399 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 001 | 2 | NIH | 3/17/2025 | $501,086 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA299070 | Electronic Nose Technology to Predict and Assess Pathologic Response After Neoadjuvant Therapy and Recurrence for Non-Small Cell Lung Cancer | 000 | 1 | NIH | 6/16/2025 | $452,540 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 002 | 2 | NIH | 5/22/2025 | $55,676 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290400 | Investigating hypoxia as a determinant of malignant fates in pancreas cancer | 001 | 2 | NIH | 5/26/2025 | $69,512 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290400 | Investigating hypoxia as a determinant of malignant fates in pancreas cancer | 000 | 2 | NIH | 3/3/2025 | $625,610 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS126921 | Chemical Genetic Dissection of SWI/SNF Chromatin Remodeling Complex Functions in Cerebral Cortex Development | 000 | 3 | NIH | 3/20/2025 | $509,034 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 001 | 5 | NIH | 5/22/2025 | $52,119 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 5 | NIH | 3/19/2025 | $469,069 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 001 | 5 | NIH | 4/29/2025 | $24,899 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 000 | 5 | NIH | 3/6/2025 | $224,101 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI150999 | HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | 000 | 5 | NIH | 2/25/2025 | $688,546 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 001 | 5 | NIH | 5/28/2025 | $62,218 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 000 | 5 | NIH | 2/19/2025 | $559,979 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 001 | 4 | NIH | 5/22/2025 | $45,703 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 000 | 4 | NIH | 3/20/2025 | $411,339 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 001 | 5 | NIH | 5/22/2025 | $46,574 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 000 | 5 | NIH | 3/5/2025 | $419,169 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA252633 | Behavioral Activation for Depression in Older Adult Cancer Survivors: Pilot Randomized Control Trial and Implementation Outcomes | 000 | 5 | NIH | 2/28/2025 | $174,699 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA248289 | Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient | 000 | 6 | NIH | 3/3/2025 | $545,622 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA279922 | Defining the role of GNAS in gastrointestinal metastasis | 000 | 3 | NIH | 2/28/2025 | $268,826 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 001 | 2 | NIH | 6/17/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 000 | 2 | NIH | 2/18/2025 | $135,224 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA293974 | Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) | 000 | 1 | NIH | 3/11/2025 | $700,611 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297030 | Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors | 000 | 1 | NIH | 2/25/2025 | $145,336 |
|
